Similar articles for PMID: 17695551

Year	Number of Results
1992	1
1994	1
1996	2
1997	1
1998	4
1999	1
2000	5
2001	6
2002	5
2003	3
2004	3
2005	4
2006	6
2007	14
2008	17
2009	17
2010	4
2011	5
2012	5
2013	3
2014	1
2017	1
2021	0

1

STEALTH liposomal CKD-602, a topoisomerase I inhibitor, improves the therapeutic index in human tumor xenograft models.

Yu NY, Conway C, Pena RL, Chen JY. Yu NY, et al. Anticancer Res. 2007 Jul-Aug;27(4B):2541-5. Anticancer Res. 2007. PMID: 17695551 Free article.

2

Plasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts.

Zamboni WC, Strychor S, Joseph E, Walsh DR, Zamboni BA, Parise RA, Tonda ME, Yu NY, Engbers C, Eiseman JL. Zamboni WC, et al. Clin Cancer Res. 2007 Dec 1;13(23):7217-23. doi: 10.1158/1078-0432.CCR-07-1035. Clin Cancer Res. 2007. PMID: 18056203 Free article.

3

Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts.

Pratesi G, De Cesare M, Carenini N, Perego P, Righetti SC, Cucco C, Merlini L, Pisano C, Penco S, Carminati P, Vesci L, Zunino F. Pratesi G, et al. Clin Cancer Res. 2002 Dec;8(12):3904-9. Clin Cancer Res. 2002. PMID: 12473606 Free article.

4

Tumor disposition of pegylated liposomal CKD-602 and the reticuloendothelial system in preclinical tumor models.

Zamboni WC, Eiseman JL, Strychor S, Rice PM, Joseph E, Zamboni BA, Donnelly MK, Shurer J, Parise RA, Tonda ME, Yu NY, Basse PH. Zamboni WC, et al. J Liposome Res. 2011 Mar;21(1):70-80. doi: 10.3109/08982101003754385. Epub 2010 Jun 9. J Liposome Res. 2011. PMID: 20528623

5

Encapsulation of the topoisomerase I inhibitor GL147211C in pegylated (STEALTH) liposomes: pharmacokinetics and antitumor activity in HT29 colon tumor xenografts.

Colbern GT, Dykes DJ, Engbers C, Musterer R, Hiller A, Pegg E, Saville R, Weng S, Luzzio M, Uster P, Amantea M, Working PK. Colbern GT, et al. Clin Cancer Res. 1998 Dec;4(12):3077-82. Clin Cancer Res. 1998. PMID: 9865923 Free article.

6

Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies.

Zamboni WC, Strychor S, Maruca L, Ramalingam S, Zamboni BA, Wu H, Friedland DM, Edwards RP, Stoller RG, Belani CP, Ramanathan RK. Zamboni WC, et al. Clin Pharmacol Ther. 2009 Nov;86(5):519-26. doi: 10.1038/clpt.2009.141. Epub 2009 Aug 12. Clin Pharmacol Ther. 2009. PMID: 19675541 Clinical Trial.

7

Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan.

Emerson DL, Bendele R, Brown E, Chiang S, Desjardins JP, Dihel LC, Gill SC, Hamilton M, LeRay JD, Moon-McDermott L, Moynihan K, Richardson FC, Tomkinson B, Luzzio MJ, Baccanari D. Emerson DL, et al. Clin Cancer Res. 2000 Jul;6(7):2903-12. Clin Cancer Res. 2000. PMID: 10914740 Free article.

8

Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor.

Lee JH, Lee JM, Kim JK, Ahn SK, Lee SJ, Kim MY, Jew SS, Park JG, Hong CI. Lee JH, et al. Arch Pharm Res. 1998 Oct;21(5):581-90. doi: 10.1007/BF02975379. Arch Pharm Res. 1998. PMID: 9875499

9

Intermittent exposure of medulloblastoma cells to topotecan produces growth inhibition equivalent to continuous exposure.

Danks MK, Pawlik CA, Whipple DO, Wolverton JS. Danks MK, et al. Clin Cancer Res. 1997 Oct;3(10):1731-8. Clin Cancer Res. 1997. PMID: 9815557 Free article.

10

Comparison of the pharmacological profile of an olivacine derivative and a potential prodrug.

Kraus-Berthier L, Guilbaud N, Léonce S, Parker T, Genissel P, Guillonneau C, Goldstein S, Atassi G, Pierré A. Kraus-Berthier L, et al. Cancer Chemother Pharmacol. 2002 Aug;50(2):95-103. doi: 10.1007/s00280-002-0481-z. Epub 2002 Jun 25. Cancer Chemother Pharmacol. 2002. PMID: 12172972

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed